{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:16:00Z","timestamp":1786115760410,"version":"build-2736575974"},"posted":{"date-parts":[[2026,8,6]]},"group-title":"In Review","reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,7,15]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <bold>Background<\/bold>\n                  Many patients with opioid use disorder (OUD) could benefit from long-acting injectable buprenorphine (LAIB), but it is not broadly available. This study examined the implementation of LAIB in three clinics (one primary care and two \u201clow-threshold\u201d clinics at syringe services programs (SSP)). Objectives were to identify implementation determinants (i.e., barriers and facilitators) at the organization, staff, and patient levels to inform development of tailored implementation strategies for each setting.\n                  <bold>Methods<\/bold>\n                  Researchers conducted semi-structured, qualitative interviews with staff (N\u2009=\u200923) and people with OUD who had lived experience with buprenorphine (N\u2009=\u200915) during early LAIB implementation at one primary care and two low-threshold clinics in New York City. Meeting notes from multidisciplinary clinical implementation working groups with staff (N\u2009=\u200927) served as an additional data source. Qualitative data collection and subsequent rapid qualitative analysis focused on implementation determinants by CFIR domain: the Innovation (LAIB), Individuals (staff and people with OUD), Inner Setting (organizational factors), and Outer Setting (external to where implementation is taking place), and recommendations for developing implementation strategies.\n                  <bold>Results<\/bold>\n                  In the Individuals domain, although staff were generally enthusiastic about implementing LAIB, they lacked comfort in counseling about LAIB, which necessitated tailored training and ongoing support. People with OUD expressed a need for detailed information about LAIB (e.g., side effects, withdrawal experiences, duration of effect) and suggested a peer messenger as an information source. Strong leadership support, clinical champions, and prior experience with sublingual buprenorphine helped overcome challenges in the Inner Setting. In the Outer Setting, the requirements to obtain LAIB from specialty pharmacies and federal regulations regarding controlled substance storage posed challenges for clinics.\n                  <bold>Conclusions<\/bold>\n                  In examining early implementation of LAIB in primary care and low-threshold clinics, multi-level barriers were identified as targets for implementation strategy development, including staff training needs, pharmacy access, and regulatory requirements. Favorable staff attitudes, strong leadership support, and local clinical champions helped overcome implementation barriers. These results can guide clinics in choosing implementation strategies and strengthen readiness for successful integration of LAIB.\n                <\/p>","DOI":"10.21203\/rs.3.rs-10374464\/v1","type":"posted-content","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:21:57Z","timestamp":1785993717000},"source":"Crossref","is-referenced-by-count":0,"title":["How should low-threshold and primary care clinics prepare to provide long-acting injectable buprenorphine? A qualitative implementation study of patient and staff perspectives"],"prefix":"10.21203","author":[{"given":"Andrea","family":"Jakubowski","sequence":"first","affiliation":[{"name":"Albert Einstein College of Medicine\/Montefiore Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Lamont","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine\/Montefiore Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zina","family":"Huxley-Reicher","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine\/Montefiore Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj V.","family":"Patel","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine\/Montefiore Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hayes","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine\/Montefiore Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Spratt","sequence":"additional","affiliation":[{"name":"OnPoint New York City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Gibson","sequence":"additional","affiliation":[{"name":"OnPoint New York City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Fox","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine\/Montefiore Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Harocopos","sequence":"additional","affiliation":[{"name":"New York University Grossman School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder | FDA [Internet]. 2023 [cited 2026 Feb 3]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorder"},{"issue":"3","key":"ref2","doi-asserted-by":"publisher","DOI":"10.52965\/001C.37517","article-title":"Buprenorphine and its formulations: a comprehensive review","volume":"10","author":"Poliwoda S","year":"2022","unstructured":"Poliwoda S, Noor N, Jenkins JS, Stark CW, Steib M, Hasoon J, et al. Buprenorphine and its formulations: a comprehensive review. Health Psychol Res. 2022;10(3). 10.52965\/001C.37517.","journal-title":"Health Psychol Res"},{"issue":"1","key":"ref3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1377\/hlthaff.2018.05145","article-title":"Trends in buprenorphine prescribing by physician specialty","volume":"38","author":"Wen H","year":"2019","unstructured":"Wen H, Borders TF, Cummings JR. Trends in buprenorphine prescribing by physician specialty. Health Aff. 2019;38(1):24\u20138. 10.1377\/hlthaff.2018.05145 . PubMed PMID: 30615523.","journal-title":"Health Aff"},{"issue":"12","key":"ref4","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1111\/add.16652","article-title":"Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018\u20132022","volume":"119","author":"Ross RK","year":"2024","unstructured":"Ross RK, Rudolph KE, Shover CL. Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018\u20132022. Addiction. 2024;119(12):2211\u20135. 10.1111\/add.16652 . PubMed PMID: 39149781.","journal-title":"Addiction"},{"issue":"10173","key":"ref5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0140-6736","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight BR","year":"2019","unstructured":"Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;393(10173):778\u201390. 10.1016\/S0140-6736. (18)32259-1 PubMed PMID: 30792007.","journal-title":"Lancet"},{"issue":"4","key":"ref6","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/S40262-020-00957-0","article-title":"Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials","volume":"60","author":"Jones AK","year":"2020","unstructured":"Jones AK, Ngaimisi E, Gopalakrishnan M, Young MA, Laffont CM. Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials. Clin Pharmacokinet. 2020;60(4):527. 10.1007\/S40262-020-00957-0 . PubMed PMID: 33135125.","journal-title":"Clin Pharmacokinet"},{"key":"ref7","author":"Marsden J","year":"2023","unstructured":"Marsden J, Kelleher M, Gilvarry E, Mitcheson L, Bisla J, Cape A et al. Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial [Internet]. 2023. Available from: www.thelancet.com"},{"issue":"6","key":"ref8","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder","volume":"178","author":"Lofwall MR","year":"2018","unstructured":"Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, et al. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder. JAMA Intern Med. 2018;178(6):764. 10.1001\/jamainternmed.2018.1052.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"E374","DOI":"10.1097\/ADM.0000000000001213","article-title":"Real-world Evidence for Impact of Opioid Agonist Therapy on Nonfatal Overdose in Patients with Opioid Use Disorder during the COVID-19 Pandemic","volume":"17","author":"Lee K","year":"2023","unstructured":"Lee K, Zhao Y, Merali T, Fraser C, Kozicky JM, Mormont MC, et al. Real-world Evidence for Impact of Opioid Agonist Therapy on Nonfatal Overdose in Patients with Opioid Use Disorder during the COVID-19 Pandemic. J Addict Med. 2023;17(6):E374\u201381. 10. 1097\/ADM.0000000000001213 PubMed PMID: 37934531.","journal-title":"J Addict Med"},{"issue":"1","key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40352-024-00281-w","article-title":"Community buprenorphine continuation post-release following extended release vs. sublingual buprenorphine during incarceration: a pilot project in Maine","volume":"12","author":"O'Connor AB","year":"2024","unstructured":"O'Connor AB, Gelsinger C, Donovan SM, Marshall J, Ahrens KA. Community buprenorphine continuation post-release following extended release vs. sublingual buprenorphine during incarceration: a pilot project in Maine. Health Justice. 2024;12(1). 10.1186\/s40352-024-00281-w.","journal-title":"Health Justice"},{"issue":"9","key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.23032","article-title":"Comparison of Treatment Retention of Adults with Opioid Addiction Managed with Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release from Jail","volume":"4","author":"Lee JD","year":"2021","unstructured":"Lee JD, Malone M, McDonald R, Cheng A, Vasudevan K, Tofighi B, et al. Comparison of Treatment Retention of Adults with Opioid Addiction Managed with Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release from Jail. JAMA Netw Open. 2021;4(9). 10.1001\/jamanetworkopen.2021.23032 . PubMed PMID: 34495340.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"ref12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/00952990.2021.1992773","article-title":"Extended-release buprenorphine outcomes among treatment resistant veterans","volume":"48","author":"Cotton AJ","year":"2022","unstructured":"Cotton AJ, Lo K, Kurtz FB, Waldbauer LA. Extended-release buprenorphine outcomes among treatment resistant veterans. Am J Drug Alcohol Abuse. 2022;48(3):334\u20137. 10.1080\/00952990.2021.1992773 . PubMed PMID: 34780319.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108316","article-title":"Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series","volume":"126","author":"Peckham AM","year":"2021","unstructured":"Peckham AM, Kehoe LG, Gray JR, Wakeman SE. Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series. J Subst Abuse Treat. 2021;126. 10.1016\/j.jsat.2021.108316 . PubMed PMID: 34116808.","journal-title":"J Subst Abuse Treat"},{"issue":"11","key":"ref14","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jama.2025.27019","article-title":"Emergency Department\u2013Initiated Buprenorphine for Opioid Use Disorder","volume":"335","author":"D'Onofrio G","year":"2026","unstructured":"D'Onofrio G, Herring AA, Hawk KF, Perrone J, Cowan E, McCormack RP, et al. Emergency Department\u2013Initiated Buprenorphine for Opioid Use Disorder. JAMA. 2026;335(11):948. 10.1001\/jama.2025.27019.","journal-title":"JAMA"},{"issue":"1","key":"ref15","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1186\/s12913-021-07196-4","article-title":"Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review","volume":"21","author":"Medlinskiene K","year":"2021","unstructured":"Medlinskiene K, Tomlinson J, Marques I, Richardson S, Stirling K, Petty D. Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review. BMC Health Serv Res. 2021;21(1):1198. 10.1186\/s12913-021-07196-4.","journal-title":"BMC Health Serv Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2025.100328","article-title":"Long acting injectable buprenorphine: Perspectives from service-users, staff and stakeholders","volume":"15","author":"Fish R","year":"2025","unstructured":"Fish R, Mateus C, Maiden H, Lawson E, Limmer M. Long acting injectable buprenorphine: Perspectives from service-users, staff and stakeholders. Drug Alcohol Depend Rep. 2025;15. 10.1016\/j.dadr.2025.100328.","journal-title":"Drug Alcohol Depend Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104359","article-title":"Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence","volume":"126","author":"Lancaster K","year":"2024","unstructured":"Lancaster K, Gendera S, Treloar C, Rhodes T, Shahbazi J, Byrne M, et al. Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence. Int J Drug Policy. 2024;126. 10.1016\/j.drugpo.2024.104359 . PubMed PMID: 38382354.","journal-title":"Int J Drug Policy"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108781","article-title":"Long-acting depot buprenorphine in people who are homeless: Views and experiences","volume":"139","author":"Matheson C","year":"2022","unstructured":"Matheson C, Foster R, Schofield J, Browne T. Long-acting depot buprenorphine in people who are homeless: Views and experiences. J Subst Abuse Treat. 2022;139. 10.1016\/j.jsat.2022.108781 . PubMed PMID: 35450752.","journal-title":"J Subst Abuse Treat"},{"issue":"7","key":"ref19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5055\/jom.2021.0643","article-title":"Interest in long-acting injectable buprenorphine among syringe services program participants","volume":"17","author":"Epstein H","year":"2021","unstructured":"Epstein H, Perez-Correa A, Beltre J, Fitzsimmons C, Marcus P, Ramirez F, et al. Interest in long-acting injectable buprenorphine among syringe services program participants. J Opioid Manag. 2021;17(7):59\u201367. 10.5055. \/JOM.2021.0643 PubMed PMID: 34520027.","journal-title":"J Opioid Manag"},{"issue":"1","key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-022-00474-2","article-title":"Patient perspectives on depot buprenorphine treatment for opioid addiction \u2013 a qualitative interview study","volume":"17","author":"Johnson B","year":"2022","unstructured":"Johnson B, Flensburg OL, Capusan AJ. Patient perspectives on depot buprenorphine treatment for opioid addiction \u2013 a qualitative interview study. Subst Abuse Treat Prev Policy. 2022;17(1). 10.1186\/s13011-022-00474-2 . PubMed PMID: 35614466.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104221","article-title":"Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study","volume":"122","author":"Parkin S","year":"2023","unstructured":"Parkin S, Neale J, Strang J. Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study. Int J Drug Policy. 2023;122. 10.1016\/j.drugpo.2023.104221 . PubMed PMID: 37865052.","journal-title":"Int J Drug Policy"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108959","article-title":"Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia","volume":"227","author":"Barnett A","year":"2021","unstructured":"Barnett A, Savic M, Lintzeris N, Bathish R, Arunogiri S, Dunlop AJ, et al. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia. Drug Alcohol Depend. 2021;227. 10.1016\/j.drugalcdep.2021.108959 . PubMed PMID: 34450472.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"ref23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/00914509221140959","article-title":"The Social, Material, and Temporal Effects of Monthly Extended-Release Buprenorphine Depot Treatment for Opioid Dependence: An Australian Qualitative Study","volume":"50","author":"Lancaster K","year":"2023","unstructured":"Lancaster K, Gendera S, Treloar C, Rhodes T, Shahbazi J, Byrne M, et al. The Social, Material, and Temporal Effects of Monthly Extended-Release Buprenorphine Depot Treatment for Opioid Dependence: An Australian Qualitative Study. Contemp Drug Probl. 2023;50(1):105\u201320. 10.1177\/00914509221140959.","journal-title":"Contemp Drug Probl"},{"issue":"1","key":"ref24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13722-024-00458-6","article-title":"Healthcare staff's perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study","volume":"19","author":"Nordgren J","year":"2024","unstructured":"Nordgren J, Monwell B, Johnson B, Gunnarsson NV, Capusan AJ. Healthcare staff's perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study. Addict Sci Clin Pract. 2024;19(1):25. 10.1186\/s13722-024-00458-6.","journal-title":"Addict Sci Clin Pract"},{"key":"ref25","author":"Tuazon E","year":"2025","unstructured":"Tuazon E, Weitz A, Sun T, Gasdaska B, Clarke-Crichton G, Samaroo B et al. Unintentional Drug Poisoning (Overdose) Deaths in New York City in 2024. New York City Department of Health and Mental Hygiene: Epi Data Brief. 2025;150."},{"key":"ref26","author":"McAteer JM","year":"2024","unstructured":"McAteer JM, Mantha S, Gibson BE, Fulmer C, Harocopos A, See K, et al. New Engl J Med Catalyst. 2024;5(5). 10.1056\/CAT.23.0341. NYC's Overdose Prevention Centers: Data from the First Year of Supervised Consumption Services."},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/ADM.0000000000000934","article-title":"Low-threshold Buprenorphine Treatment in a Syringe Services Program: Program Description and Outcomes","volume":"16","author":"Jakubowski A","year":"2022","unstructured":"Jakubowski A, Norton BL, Hayes BT, Gibson BE, Fitzsimmons C, Stern LS, et al. Low-threshold Buprenorphine Treatment in a Syringe Services Program: Program Description and Outcomes. J Addict Med. 2022;16(4):447\u201353. 10. 1097\/ADM.0000000000000934 PubMed PMID: 34775441.","journal-title":"J Addict Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108778","article-title":"Cascade of care for office-based buprenorphine treatment in Bronx community clinics","volume":"139","author":"Khalid L","year":"2022","unstructured":"Khalid L, Cunningham CO, Deng Y, Masyukova M, Bumol J, Valle A, et al. Cascade of care for office-based buprenorphine treatment in Bronx community clinics. J Subst Abuse Treat. 2022;139. 10.1016\/j.jsat.2022.108778 . PubMed PMID: 35428524.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-015-0209-1","article-title":"A refined compilation of implementation strategies: Results from the Expert Recommendations for Implementing Change (ERIC) project","volume":"10","author":"Powell BJ","year":"2015","unstructured":"Powell BJ, Waltz TJ, Chinman MJ, Damschroder LJ, Smith JL, Matthieu MM, et al. A refined compilation of implementation strategies: Results from the Expert Recommendations for Implementing Change (ERIC) project. Implement Sci. 2015;10(1). 10.1186\/s13012-015-0209-1 . PubMed PMID: 25889199.","journal-title":"Implement Sci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s11414-020-09709-1","author":"Siantz E","year":"2021","unstructured":"Siantz E, Redline B, Henwood B. Practice Facilitation in Integrated Behavioral Health and Primary Care Settings: a Scoping Review. Journal of Behavioral Health Services and Research. Springer; 2021. pp. 133\u201355. 10.1007\/s11414-020-09709-1 PubMed PMID: 32458281."},{"issue":"12","key":"ref31","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s11606-024-09260-1","article-title":"The Implementation Climate for Integrating Buprenorphine Prescribing into Rural Primary Care","volume":"40","author":"Fenstemaker C","year":"2025","unstructured":"Fenstemaker C, Abrams EA, King K, Obringer B, Brook DL, Go V, et al. The Implementation Climate for Integrating Buprenorphine Prescribing into Rural Primary Care. J Gen Intern Med. 2025;40(12):2879\u201389. 10.1007\/s11606-024-09260-1 . PubMed PMID: 39668316.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"ref32","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/08897077.2021.1901173","article-title":"We'll be able to take care of ourselves\u2013A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs","volume":"42","author":"Frost T","year":"2021","unstructured":"Frost T, Deutsch S, Brown S, Lemien E, Cunningham CO, Fox AD. We'll be able to take care of ourselves\u2013A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs. Subst Abus. 2021;42(4):983\u20139. 10.1080\/08897077.2021.1901173 . PubMed PMID: 33759722.","journal-title":"Subst Abus"},{"issue":"1","key":"ref33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12875-019-1047-z","article-title":"Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review","volume":"20","author":"Louie DL","year":"2019","unstructured":"Louie DL, Assefa MT, McGovern MP. Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review. BMC Fam Pract. 2019;20(1):157. 10.1186\/s12875-019-1047-z.","journal-title":"BMC Fam Pract"},{"issue":"1","key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-019-0296-4","article-title":"Prolonged-release opioid agonist therapy: Qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations","volume":"16","author":"Neale J","year":"2019","unstructured":"Neale J, Tompkins CNE, Strang J. Prolonged-release opioid agonist therapy: Qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations. Harm Reduct J. 2019;16(1). 10.1186\/s12954-019-0296-4 . PubMed PMID: 30943990.","journal-title":"Harm Reduct J"},{"issue":"5","key":"ref35","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/dar.12939","article-title":"Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences","volume":"38","author":"Neale J","year":"2019","unstructured":"Neale J, Tompkins CNE, Strang J. Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences. Drug Alcohol Rev. 2019;38(5):510\u20138. 10.1111\/dar.12939 . PubMed PMID: 31131514.","journal-title":"Drug Alcohol Rev"},{"issue":"10","key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019993","article-title":"Can rapid approaches to qualitative analysis deliver timely, valid findings to clinical leaders? A mixed methods study comparing rapid and thematic analysis","volume":"8","author":"Taylor B","year":"2018","unstructured":"Taylor B, Henshall C, Kenyon S, Litchfield I, Greenfield S. Can rapid approaches to qualitative analysis deliver timely, valid findings to clinical leaders? A mixed methods study comparing rapid and thematic analysis. BMJ Open. 2018;8(10). 10.1136\/bmjopen-2017-019993 . PubMed PMID: 30297341.","journal-title":"BMJ Open"},{"key":"ref37","unstructured":"Providers Clinical Support. System-Medications for Opioid Use Disorders (PCSS-MOUD) [Internet]. [cited 2025 Dec 15]. Available from: https:\/\/pcssnow.org\/"},{"issue":"1","key":"ref38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/08897077.2015.1129388","article-title":"Project ECHO (Extension for Community Healthcare Outcomes): A new model for educating primary care providers about treatment of substance use disorders","volume":"37","author":"Komaromy M","year":"2016","unstructured":"Komaromy M, Duhigg D, Metcalf A, Carlson C, Kalishman S, Hayes L, et al. Project ECHO (Extension for Community Healthcare Outcomes): A new model for educating primary care providers about treatment of substance use disorders. Subst Abus. 2016;37(1):20\u20134. 10.1080\/08897077.2015.1129388.","journal-title":"Subst Abus"},{"key":"ref39","unstructured":"Grayken Center for Addiction Training and Technical Assistance. | Boston Medical Center [Internet]. [cited 2025 Dec 15]. Available from: https:\/\/www.addictiontraining.org\/"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1224376","article-title":"Implementing buprenorphine prolonged-release injection using a health at the margins approach for transactional sex-workers","volume":"14","author":"Gittins R","year":"2023","unstructured":"Gittins R, Teck JTW, Knowles R, Clarke N, Baldacchino A. Implementing buprenorphine prolonged-release injection using a health at the margins approach for transactional sex-workers. Front Psychiatry. 2023;14. 10.3389\/fpsyt.2023.1224376.","journal-title":"Front Psychiatry"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104399","article-title":"The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences","volume":"127","author":"Barnett A","year":"2024","unstructured":"Barnett A, Pienaar K, Lubman DI, Arunogiri S, Phan V, Hayes V, et al. The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences. Int J Drug Policy. 2024;127. 10.1016\/j.drugpo.2024.104399 . PubMed PMID: 38636315.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxae024","article-title":"US payment policy for medications to treat opioid use disorder: landscape and opportunities","volume":"2","author":"McGinty EE","year":"2024","unstructured":"McGinty EE, White SA, Eisenberg MD, Palmer NR, Brown CH, Saloner BK. US payment policy for medications to treat opioid use disorder: landscape and opportunities. Health Affairs Scholar. 2024;2(3). 10.1093\/haschl\/qxae024.","journal-title":"Health Affairs Scholar"},{"issue":"6","key":"ref43","doi-asserted-by":"crossref","first-page":"e2318487","DOI":"10.1001\/jamanetworkopen.2023.18487","article-title":"Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements","volume":"6","author":"Nguemeni Tiako MJ","year":"2023","unstructured":"Nguemeni Tiako MJ, Dolan A, Abrams M, Oyekanmi K, Meisel Z, Aronowitz SV. Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements. JAMA Netw Open. 2023;6(6):e2318487. 10.1001\/. JAMANETWORKOPEN.2023.18487 PubMed PMID: 37318805.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"ref44","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1377\/hlthaff.2022.01513","article-title":"Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017\u201321","volume":"42","author":"Andraka-Christou B","year":"2023","unstructured":"Andraka-Christou B, Simon KI, Bradford WD, Nguyen T. Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017\u201321. Health Aff. 2023;42(5):658\u201364. 10.1377\/hlthaff.2022.01513.","journal-title":"Health Aff"},{"issue":"1","key":"ref45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13012-022-01245-0","article-title":"The updated Consolidated Framework for Implementation Research based on user feedback","volume":"17","author":"Damschroder LJ","year":"2022","unstructured":"Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated Consolidated Framework for Implementation Research based on user feedback. Implement Sci 2022. 2022;17(1):1. 10.1186\/S13012-022-01245-0 . PubMed PMID: 36309746.","journal-title":"Implement Sci 2022"},{"key":"ref46","first-page":"52","article-title":"Community Engagement in Implementation Science: the Impact of Community Engagement Activities in the DECIPHeR Alliance","author":"Cooper C","unstructured":"Cooper C, Watson K, Alvarado F, Carroll AJ, Carson SL, Donenberg G et al. Community Engagement in Implementation Science: the Impact of Community Engagement Activities in the DECIPHeR Alliance. Ethn Dis 2024;DECIPHeR(Spec Issue):52. 10.18865\/ED.DECIPHER.52 PubMed PMID: 38846725.","journal-title":"Ethn Dis 2024;DECIPHeR(Spec Issue)"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10374464\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10374464\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:21:59Z","timestamp":1785993719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10374464\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":46,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-10374464\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,8,6]]},"subtype":"preprint"}}